Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-PN1
NL-OMON59767Phase 3Completed
- Sponsor
- Incyte
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of povorcitinib in prurigo nodularis (PN), sponsored by Incyte. Primary endpoint: Composite Itch NRS4 and IGA-CPG-S-TS response at Week 24. Started Jan 2025; status: completed.
02
Drugs
povorcitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NL-OMON59767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59767.